147643-61-6

Upstream product

• 74-89-5 methylamine 
• 156300-02-6 (S)-2-(3,4-dichlorophenyl)pent-4-enoyl chloride 
• 6831-55-6 2-(3,4-dichlorophenyl)acetyl chloride 
• 250788-94-4 (S)-4-benzyl-3-(2-(3,4-dichlorophenyl)pent-4-enoyl)-2-oxazolidinone 
• 147643-58-1 (S)-4-benzyl-3-(3,4-dichlorophenyl)acetyl-2-oxazolidinone 
• 147643-57-0 (2S)-2-(3,4-dichlorophenyl)pent-4-enoic acid 
• 79333-48-5 2-(S)-(3,4-dichloro-phenyl)-4-pentenoic acid 
• 5807-30-7 3,4-dichlorophenyl acetic acid 

Downstream Products

• 774244-66-5 N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-3-nitro-benzamide 
• 774244-65-4 N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-2-nitro-benzamide 
• 774244-67-6 N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-4-nitro-benzamide 
• 774244-70-1 4-amino-N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-benzamide 
• 774244-69-8 3-amino-N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-benzamide 
• 774244-68-7 2-amino-N-[2-(3,4-dichloro-phenyl)-4-(4-hydroxy-4-phenyl-piperidin-1-yl)-butyl]-N-methyl-benzamide 

Relevant academic research and scientific papers

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl) butanes

Screening of the Merck sample collection for compounds with CCR5 receptor binding afforded (2S)-2-(3,4-dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2 ,3-dihydrobenzthiophene-3,4′-piperidin-1′-yl)]butane S-oxide (4) as a potent lead structure having an IC50 binding affinity of 35 nM. Herein, we describe the discovery of this lead structure and our initial structure-activity relationship studies directed toward the requirement for and optimization of the 1-amino fragment.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes

(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2 ,3-dihydrobenzthiophene-3,4′-piperidin-1′yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16: X = H, 3-F, 3-Cl, 3-Me).